ABSTRACT
The identification of the cellular receptor used by viruses to enter their target cells is always a challenge and to date entry receptors remain to be identified for a variety of pathogenic human viruses. Human T-lymphotropic virus type 1 (HTLV-1), the unique oncogenic retrovirus in human, was identified in the early 1980 's. The nature of its entry receptor has remained a mystery for over 20 years, until the independent identification of three proteins presenting the expected criteria, the glucose transporter Glut1, Neuropilin 1, a VEGF receptor, and heparan sulfate proteoglycans. In this review, we summarize the data pertaining to HTLV-1 entry molecules and present a new model, in which these three proteins successively intervene during the entry process.
Subject(s)
Anemia/complications , Anemia/drug therapy , Erythrocytes/cytology , Erythropoietin/therapeutic use , Granulomatous Disease, Chronic/complications , Granulomatous Disease, Chronic/drug therapy , Steroids/therapeutic use , Adult , Anemia/pathology , Follow-Up Studies , Granulomatous Disease, Chronic/pathology , Hemoglobins/metabolism , Humans , Male , Phenotype , Reticulocyte CountABSTRACT
Hepatitis C virus (HCV) has been associated with the development of B-cell non-Hodgkin lymphomas. We recently reported the regression of splenic lymphoma with villous lymphocytes (SLVL) in patients with HCV after antiviral treatment, demonstrating a direct role of HCV in lymphomagenesis. This study expands our previous results in 18 patients with chronic HCV and SLVL. Mixed cryoglobulinemia (MC) was present in all cases and was symptomatic in 13 (72%). All patients were treated with interferon alone or in association with ribavirin. Hematologic and virologic responses were correlated. Fourteen (78%) patients achieved a sustained complete hematologic response after clearance of HCV RNA. Two patients had a virologic partial response and achieved a complete hematologic response. Two virologic nonresponders achieved partial hematologic response. Regardless of the response, monoclonal immunoglobulin gene rearrangement persisted after treatment. This study underscores the role of HCV in the lymphomagenesis and the benefit of antiviral treatment for patients presenting with HCV-driven lymphoproliferations.
